Nonacus introduces ExomeCG product to simplify molecular and cytogenomics data generation and interpretation
Birmingham, UK, 16 October 2019: Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product to simplify the generation and interpretation of molecular and cytogenomic data.
The new product has been co-developed with digital health technology company, Congenica Ltd, which specialises in software solutions that enable accelerated interpretation of complex genomic data to improve disease diagnosis.
ExomeCG is a clinically enhanced exome capture kit which, for the first time, will enable the genomics community to perform confident and robust whole exome sequencing and targeted copy number analysis in a single assay. The clinically validated test replaces the need for chromosomal microarray and multiplex ligation-dependent probe amplification (MLPA) front line tests, saving time and cost while achieving the highest diagnostic yield possible.
ExomeCG is designed to provide unparalleled coverage of clinical targets when used in combination with the Congenica® clinical decision support platform, which enables fast and accurate interpretation of NGS data for healthcare professionals to deliver world-class genomic medicine services and make important clinical decisions. Under the agreement Nonacus will supply the Congenica® software platform alongside the Exome CG product and the wider Nonacus Cell3 Target™ product range, to provide an end-to-end solution for postnatal and prenatal analysis.
Chris Sale, Chief Executive Officer of Nonacus, said: “The launch of ExomeCG enables us to deliver a comprehensive clinical bioinformatics service to our customers and advance clinical cytogenomics by providing a robust, cost effective and user-friendly laboratory and analysis workflow.The current cytogenomics paradigm typically requires a multi-test strategy whereby chromosomal microarrays are first run achieving a modest 15% diagnostic yield. Subsequently, exome sequencing is undertaken in order to raise the diagnostic yield to around 40%. ExomeCG now offers a validated single test solution, enabling customers to obtain the highest diagnostic yield while removing additional workflows and the associated time and costs.”
ENDS
Notes for Editors
For further information please contact:
Zyme Communications
Lorna Cuddon
Tel: +44 (0)7811 996 942
Email: [email protected]
To opt-out from receiving press releases from Zyme Communications please e-mail [email protected]. To view our privacy policy, please click here.
About Nonacus www.nonacus.com
Nonacus is a precision medicine company and developer of innovative genomic healthcare solutions.
Based in Birmingham UK, the company develops novel NGS library preparation solutions primarily in the non-invasive healthcare space and based on next-generation sequencing, targeted DNA sequencing and real-time qPCR kits.
Nonacus products are designed to help customers analyse the most difficult of samples with a particular focus on cfDNA and FFPE. Allowing samples to be processed faster and with greater sensitivity and accuracy, while being compatible with leading instrumentation.
About Congenica www.congenica.com
Congenica is a digital health technology company with the world’s leading clinical decision support platform for accelerated genomic data interpretation. Congenica software enables genomic medicine by integrating genetic data into healthcare, empowering clinicians to provide life-changing answers that transform the lives of individuals, patients and their families.
Genetic diseases are technically difficult to diagnose, and patients often spend years waiting for a diagnosis. Congenica convert genomic data into actionable information, expediting the process through more efficient and accurate analysis. This supports healthcare professionals in providing patients with robust diagnoses and precise, personalized care.
Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica is headquartered in Cambridge, UK, with a global footprint across the US and China. The Congenica platform is validated by the pivotal Genomics England 100,000 Genomes Project and is the exclusive clinical interpretation partner for the NHS Genomic Medicine Service.